Coverage
-
July 07, 2017
A Pennsylvania federal judge on Friday ended Canadian pharmaceutical company Apotex's pay-for-delay suit accusing generic-drug maker Ranbaxy of violating antitrust laws by accepting a settlement with Cephalon that improperly delayed generic alternatives to the narcolepsy medication Provigil from entry into the market.
17 other articles on this case.
View all »